J
Jasper Therapeutics, Inc. (JSPR)
NCM – Real vaqt narxi. Valyuta: USD
0.34
-0.10 (-22.99%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.35
+0.01 (2.64%)
Bozordan keyin: Jun 26, 2026, 7:56 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.34
-0.10 (-22.99%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.35
+0.01 (2.64%)
Bozordan keyin: Jun 26, 2026, 7:56 PM EDT
Jasper Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda mast hujayrali ildiz hujayralari tomonidan qo'zg'atilgan kasalliklarga qarshi terapevtik vositalarni ishlab chiqishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi - briquilimab, bu mast va ildiz hujayralaridagi CD117 retseptoriga bog'lanish va signalizatsiya qilish uchun ildiz hujayralari omillarini blokirovka qilish uchun ishlab chiqilgan monoklonal antiteladir. U surunkali spontan ürtiker, surunkali indüklanadigan ürtiker va astma kabi turli xil mast hujayralari tomonidan qo'zg'atilgan kasalliklari bo'lgan bemorlar uchun terapevtik vositalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Jasper Therapeutics, Inc. 2018-yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Redwood City shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Alex Gray | Head of Investor Relations |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
| Mr. Matthew Ford | Senior Vice President of Human Resources |
| Mr. Thomas G. Wiggans | Executive Chairman |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-15 | DEF 14A | ea0293818-01.htm |
| 2026-06-09 | 8-K | ea0294010-8k_jasper.htm |
| 2026-06-01 | 8-K | ea0292909-8k_jasper.htm |
| 2026-05-21 | 8-K | ea0291168-8k_jasper.htm |
| 2026-05-14 | 8-K | ea0290792-8k_jasper.htm |
| 2026-05-14 | 10-Q | ea0289477-10q_jasper.htm |
| 2026-04-30 | 10-K/A | ea0287356-10ka1_jasper.htm |
| 2026-03-30 | 8-K | ea0283364-8k_jasper.htm |
| 2026-03-30 | 10-K | ea0282128-10k_jasper.htm |
| 2026-01-08 | 8-K | ea0272248-8k_jasper.htm |